Our findings, as shown in Table 3, illustrated that in patients with early AD (with evidence of abnormal amyloid), clinical status, MMSE scores, aHV, FDG SUVRs, and CSF p-tau levels, which are well known factors related with rate of clinical progression (Blanco et al., 2023), were associated with the cluster membership. This evidence concerns the gene MAPT and Alzheimer disease.